BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 12384164)

  • 1. Age-related reference ranges for complexed prostate-specific antigen and complexed/total prostate-specific antigen ratio: results from East Texas Medical Center Cancer Institute screening campaign.
    Cheli CD; Levine RL; Cambetas DR; Kolker JD; Roberts SB
    Urology; 2002 Oct; 60(4 Suppl 1):53-9. PubMed ID: 12384164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter.
    Horninger W; Cheli CD; Babaian RJ; Fritsche HA; Lepor H; Taneja SS; Childs S; Stamey TA; Sokoll LJ; Chan DW; Brawer MK; Partin AW; Bartsch G
    Urology; 2002 Oct; 60(4 Suppl 1):31-5. PubMed ID: 12384160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of age on total and complexed prostate-specific antigen cutoffs in a contemporary referral series of men with prostate cancer.
    Veltri RW; Miller MC; O'dowd GJ; Partin AW
    Urology; 2002 Oct; 60(4 Suppl 1):47-52. PubMed ID: 12384163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial.
    Djavan B; Remzi M; Zlotta AR; Ravery V; Hammerer P; Reissigl A; Dobronski P; Kaisary A; Marberger M
    Urology; 2002 Oct; 60(4 Suppl 1):4-9. PubMed ID: 12384156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of age on complexed PSA levels in men with total PSA levels of up to 20 ng/mL.
    Berger AP; Cheli C; Levine R; Klocker H; Bartsch G; Horninger W
    Urology; 2003 Nov; 62(5):840-4. PubMed ID: 14624905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics.
    Miller MC; O'Dowd GJ; Partin AW; Veltri RW
    Urology; 2001 Jun; 57(6):1105-11. PubMed ID: 11377319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial.
    Partin AW; Brawer MK; Bartsch G; Horninger W; Taneja SS; Lepor H; Babaian R; Childs SJ; Stamey T; Fritsche HA; Sokoll L; Chan DW; Thiel RP; Cheli CD
    J Urol; 2003 Nov; 170(5):1787-91. PubMed ID: 14532777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Observed effect of age and body mass index on total and complexed PSA: analysis from a national screening program.
    Barqawi AB; Golden BK; O'Donnell C; Brawer MK; Crawford ED
    Urology; 2005 Apr; 65(4):708-12. PubMed ID: 15833513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of two investigative assays for the complexed prostate-specific antigen in total prostate-specific antigen between 4.1 and 10.0 ng/mL.
    Okegawa T; Noda H; Nutahara K; Higashihara E
    Urology; 2000 May; 55(5):700-4. PubMed ID: 10792084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can complexed prostate specific antigen enhance prostate cancer detection in Japanese men?
    Okihara K; Ukimura O; Nakamura T; Mizutani Y; Kawauchi A; Naya Y; Uchida M; Ogiwara T; Miki T
    Eur Urol; 2004 Jul; 46(1):57-64. PubMed ID: 15183548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of prostate cancer on repeat prostatic biopsy in men with serum total prostate-specific antigen between 4.1 and 10 ng/mL.
    Okegawa T; Kinjo M; Ohta M; Miura I; Horie S; Nutahara K; Higashihara E
    Int J Urol; 2003 Apr; 10(4):201-6. PubMed ID: 12657099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparisons of the various combinations of free, complexed, and total prostate-specific antigen for the detection of prostate cancer.
    Okegawa T; Noda H; Nutahara K; Higashihara E
    Eur Urol; 2000 Oct; 38(4):380-7. PubMed ID: 11025374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?
    Jung K; Elgeti U; Lein M; Brux B; Sinha P; Rudolph B; Hauptmann S; Schnorr D; Loening SA
    Clin Chem; 2000 Jan; 46(1):55-62. PubMed ID: 10620572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-benefit analysis of total, free/total, and complexed prostate-specific antigen for prostate cancer screening.
    Ellison L; Cheli CD; Bright S; Veltri RW; Partin AW
    Urology; 2002 Oct; 60(4 Suppl 1):42-6. PubMed ID: 12384162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The significance of the free-to-complexed prostate-specific antigen (PSA) ratio in prostate cancer detection in patients with a PSA level of 4.1-10.0 ng/mL.
    Okegawa T; Kinjo M; Watanabe K; Noda H; Kato M; Miyata A; Murata A; Yoshii M; Nutahara K; Higashihara E
    BJU Int; 2000 Apr; 85(6):708-14. PubMed ID: 10759671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complexed prostate specific antigen (PSA) reduces unnecessary prostate biopsies in the 2.6-4.0 ng/mL range of total PSA.
    Parsons JK; Brawer MK; Cheli CD; Partin AW; Djavan R
    BJU Int; 2004 Jul; 94(1):47-50. PubMed ID: 15217429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of prostate cancer with complexed PSA and complexed/total PSA ratio - is there any advantage?
    Strittmatter F; Stieber P; Nagel D; Füllhase C; Walther S; Stief CG; Waidelich R
    Eur J Med Res; 2011 Oct; 16(10):445-50. PubMed ID: 22024423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complexed PSA improves prostate cancer detection: results from a multicenter Japanese clinical trial.
    Okihara K; Ukimura O; Nakamura T; Ushijima S; Mizutani Y; Kawauchi A; Naya Y; Kojima M; Miki T
    Urology; 2006 Feb; 67(2):328-32. PubMed ID: 16461082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.
    Lein M; Jung K; Elgeti U; Petras T; Stephan C; Brux B; Sinha P; Winkelmann B; Schnorr D; Loening S
    Eur Urol; 2001 Jan; 39(1):57-64. PubMed ID: 11173940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The measurement of complexed prostate-specific antigen has a better performance than total prostate-specific antigen.
    Herrmann W; Stöckle M; Sand-Hill M; Hübner U; Herrmann M; Obeid R; Wullich B; Loch T; Geisel J
    Clin Chem Lab Med; 2004; 42(9):1051-7. PubMed ID: 15497472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.